GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
UK Banks Report Surge in APP Fraud Losses as Pressure Mounts on Meta and Tech Platforms 
Elon Musk Becomes World's First Trillionaire After SpaceX IPO Surge 
Woodside Energy Denies Exxon Mobil Takeover Talks Amid LNG Growth Focus 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Taiwan Central Bank Likely to Keep Interest Rates Unchanged Through 2027 
German Auto Suppliers Turn Bearish as Investment and Jobs Shift Overseas 
SoftBank Vision Fund CFO Navneet Govil to Exit After Decade-Long Tenure 
BOJ Raises Interest Rates to 31-Year High, Signals Strong Focus on Inflation Risks 
North Korea Reports Industrial Output at 105% of Target Following Party Congress 
BOJ Raises Interest Rates to 1% as Inflation Pressures Persist 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Trump Administration Closes Delta Air Lines Investigation Over 2024 CrowdStrike Outage 
US Stock Futures Edge Higher Ahead of Key Federal Reserve Decision 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
ASX Proposes New Share Dilution Limits for Public Takeovers 
Reckitt Benckiser announced last weekend that it is selling its Mead Johnson Nutrition company in China to Primavera Capital Group. The deal was said to be valued at $2.2 billion.
As per Reuters, while Primavera Capital has already bought Reckitt Benckiser’s infant formula and child nutrition business in China, the latter will still retain an eight percent stake in the China unit of Mead Johnson Nutrition.
Reckitt to incur a loss on the sale
Reckitt Benckiser is expecting to receive around $1.3 billion from the sale, but it is also anticipating a net loss of $3.5 billion on the disposal. The loss is said to be due to intangible assets and re-measurement of goodwill.
In any case, it was in March when it was first reported that Reckitt Benckiser was considering the sale of the Chinese unit of Mead Johnson. The company observed a sluggish sale and launched a strategic review of its infant formula and child nutrition business in China.
In the end, the sale was decided as sales are not going up anywhere, and Reckitt cited the intense competition with local baby formula brands as one of the reasons for the slow income. Also, the low birth rates in China was also blamed for the dwindling sales as there are fewer babies to feed with the infant formula.
The deal between Reckitt and Primavera
As the sale was revealed, Reckitt Beckinser shared that the deal with Primavera Capital includes the sale of the company’s production factories in Guangzhou, China, and at Nijmegen in the Netherlands. Moreover, a royalty-free perpetual and exclusive license of Mead Johnson and Enfa brands in China, including Enfagrow, Enfamil, and Enfinitas, are also included in the agreement.
Then again, it should be noted that this is only in Greater China, as Reckitt still owns and will continue to sell Mead Johnson and Enfa products in other parts of the world.
"We are pleased to acquire the Greater China business of Mead Johnson, a long-established and renowned multinational infant and children nutrition brand,” Primavera Capital Group founder and chairman, Dr. Fred Hu, said in a press release. “As the controlling shareholder, Primavera is committed to serve tens of millions of Chinese mothers and babies and safeguard their well-being.”
Finally, the Reckitt Beckinser and Primavera Capital deal is expected to close within the second half of this year.
